BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fotiou D, Gavriatopoulou M, Terpos E. Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools. Cancers (Basel) 2020;12:E191. [PMID: 31940972 DOI: 10.3390/cancers12010191] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Dhami SPS, Patmore S, O'Sullivan JM. Advances in the Management of Cancer-Associated Thrombosis. Semin Thromb Hemost 2021;47:139-49. [PMID: 33636745 DOI: 10.1055/s-0041-1722863] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ciepiela O, Małecka-Giełdowska M, Czyżewska E. Neutrophil Extracellular Traps (NETs) and Hypercoagulability in Plasma Cell Dyscrasias-Is This Phenomenon Worthy of Exploration? J Clin Med 2021;10:5243. [PMID: 34830525 DOI: 10.3390/jcm10225243] [Reference Citation Analysis]
3 Hoppe A, Rupa-Matysek J, Małecki B, Dytfeld D, Hoppe K, Gil L. Risk Factors for Catheter-Related Thrombosis in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Medicina (Kaunas) 2021;57:1020. [PMID: 34684057 DOI: 10.3390/medicina57101020] [Reference Citation Analysis]
4 Santoro M, Romano A, Mancuso S, Siragusa S, DI Raimondo F, Martinelli G, Cerchione C. Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. Panminerva Med 2021;63:1-6. [PMID: 32955183 DOI: 10.23736/S0031-0808.20.04133-6] [Reference Citation Analysis]
5 Calafiore V, Giamporcaro S, Conticello C, Romano A, Parisi M, Giuffrida G, Tibullo D, Di Raimondo F, Signorelli SS. A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents. J Clin Med 2020;9:E2876. [PMID: 32899553 DOI: 10.3390/jcm9092876] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Camilli M, La Vecchia G, Lillo R, Iannaccone G, Lamendola P, Montone RA, Hohaus S, Aspromonte N, Massetti M, Lanza GA, Crea F, Graziani F, Lombardo A. Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances. Expert Rev Hematol 2021;:1-14. [PMID: 34739762 DOI: 10.1080/17474086.2021.2003704] [Reference Citation Analysis]
7 Miceli TS, Gonsalves WI, Buadi FK. Supportive care in multiple myeloma: Current practices and advances. Cancer Treat Res Commun 2021;29:100476. [PMID: 34653748 DOI: 10.1016/j.ctarc.2021.100476] [Reference Citation Analysis]
8 Kubota S, Hara H, Hiroi Y. Current status and future perspectives of onco-cardiology: Importance of early detection and intervention for cardiotoxicity, and cardiovascular complication of novel cancer treatment. Glob Health Med 2021;3:214-25. [PMID: 34532602 DOI: 10.35772/ghm.2021.01024] [Reference Citation Analysis]
9 Terpos E, Repousis P, Lalayanni C, Hatjiharissi E, Assimakopoulou T, Vassilopoulos G, Pouli A, Spanoudakis E, Michalis E, Pangalis G, Ntanasis-Stathopoulos I, Poziopoulos C, Kyrtsonis MC, Pappa V, Symeonidis A, Georgopoulos C, Zikos PM, Gavriatopoulou M, Papadaki HA, Dadakaridou M, Karvounis-Marolachakis K, Katodritou E. Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study. J Clin Med 2021;10:1509. [PMID: 33916376 DOI: 10.3390/jcm10071509] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ferroni P, Guadagni F, Roselli M. Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer. Cancers (Basel) 2021;13:1556. [PMID: 33805252 DOI: 10.3390/cancers13071556] [Reference Citation Analysis]